Icecure Medical Ltd (ICCM) Stock Analysis
Verdict: AVOID
Surging US adoption of ProSense is a vital catalyst, but terminal cash burn and massive equity dilution risk make this a trade, not an investment.
Investment score: 38/100
Analysis as of
Is Icecure Medical Ltd stock worth reviewing? AI model thesis
The model avoids ICCM due to an unsustainable cash burn rate that likely necessitates heavy dilution before common shareholders see profit.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Icecure Medical Ltd opportunities and risks
What speaks for ICCM
- 70% Increase in U.S. ProSense System Installs
What speaks against ICCM
- Critical Cash Runway Shortfall
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ICCM | n/a | 4.0x | n/a | 36.5% | -441.6% | -106.4% |
| LFWD | n/a | 0.5x | n/a | 36.6% | -123.7% | -133.6% |
| MBAI | 2.0x | 0.0x | 1.8x | 0.0% | 0.0% | -0.6% |
| Peer median | 0.8x | 0.3x | 0.7x | 18.3% | -61.8% | -67.1% |
Frequently asked questions about Icecure Medical Ltd (ICCM)
Is ICCM stock a good investment?
The cached TradeMates AI model rates Icecure Medical Ltd as AVOID with an investment score of 38/100. The model avoids ICCM due to an unsustainable cash burn rate that likely necessitates heavy dilution before common shareholders see profit. This is algorithmic model output, not personal investment advice.
Is ICCM stock a buy?
The TradeMates model verdict for ICCM is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.